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Background
Patients with paroxysmal nocturnal hemoglobinuria (PNH) often have concurrent aplastic 
anemia (AA). This study aimed to determine whether eculizumab-treated patients show 
clinical benefit regardless of concurrent AA.
Methods
We analyzed 46 PNH patients ≥18 years of age who were diagnosed by flow cytometry 
and treated with eculizumab for more than 6 months in the prospective Korean PNH 
registry. Patients were categorized into two groups: PNH patients with concurrent AA 
(PNH/AA, N=27) and without AA (classic PNH, N=19). Biochemical indicators of intra-
vascular hemolysis, hematological laboratory values, transfusion requirement, and 
PNH-associated complications were assessed at baseline and every 6 months after ini-
tiation of eculizumab treatment.
Results
The median patient age was 46 years and median duration of eculizumab treatment was 
34 months. Treatment with eculizumab induced rapid inhibition of hemolysis. At 6-month 
follow-up, LDH decreased to near normal levels in all patients; this effect was maintained 
until the 36-month follow-up regardless of concurrent AA. Transfusion independence was 
achieved by 53.3% of patients within the first 6 months of treatment and by 90.9% after 
36 months of treatment. The mean number of RBC units transfused was significantly re-
duced, from 8.5 units during the 6 months prior to initiation of eculizumab to 1.6 units 
in the first 6 months of treatment, for the total study population; this effect was similar 
in both PNH/AA and classic PNH.
Conclusion
This study demonstrated that eculizumab is beneficial in the management of patients with 
PNH/AA, similar to classic PNH.
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Table 1. Patient characteristics and baseline laboratory findings.
Characteristics
N of patients (%)
P
Total Classic PNH PNH/AA
N of patients 46 19 27
Age (yr) 46 (18–73) 55 (18–73) 44 (27–73) 0.294a)
Gender (M/F) 25/21 11/8 14/13 0.685b)
Disease duration (mo) 62 (0.3–364.4) 43.5 (0.3–364.4) 74 (3.2–220.2) 0.439c)
Duration of eculizumab treatment 34 (6–44) 31 (6–44) 37 (12–43) 0.327c)
LDH, fold×UNL 7.3 (2.4–23.7) 7.2 (4.1–23.7) 7.4 (2.4–16.2) 0.763a)
Hemoglobin (g/dL) 9.0 (4.5–13.2) 9.3 (4.5–12.5) 8.8 (6.0–13.2) 0.517a)
Platelet count (×109/L) 147 (31–318) 181 (86–318) 144 (31–291) 0.075a)
Neutrophils (×109/L) 2.3 (0.7–11.3) 2.7 (1.5–11.3) 1.8 (0.7–5.0) 0.004a)
Reticulocytes (%) 6.3 (2.8–40.4) 6.8 (3.5–40.4) 6.0 (2.8–13.3) 0.094c)
Serum creatinine (mg/dL) 0.8 (0.4–6.4) 0.8 (0.5–3.2) 0.8 (0.4–6.4) 0.960a)
PNH clone (WBC, %) 92.8 (15.9–100) 95.5 (48.9–100) 89.8 (15.7–100) 0.208c)
PNH clone (RBC, %) 50.0 (0.1–99) 48.7 (10.6–99) 55 (0.1–93.7) 0.910a)
a)Student t-test, b)chi-squared test, c)Mann–Whitney U test.
Abbreviations: AA, aplastic anemia; LDH, lactate dehydrogenase; PNH, paroxysmal nocturnal hemoglobinuria; RBC, red blood cells; ULN, 
upper limit of normal; WBC, white blood cells.
INTRODUCTION
Paroxysmal nocturnal hemoglobinuria (PNH) is an ac-
quired hematopoietic stem cell disease characterized by the 
intravascular lysis of red blood cells (RBCs), thromboembo-
lism (TE), and bone marrow failure [1]. Aplastic anemia 
(AA) is the most frequently associated bone marrow failure 
syndrome in PNH, and it has been reported that a history 
of severe AA is present in at least one-half of all newly 
diagnosed PNH cases [2]. Eculizumab, a humanized mono-
clonal antibody that binds specifically to human complement 
protein C5 and inhibits the formation of the terminal comple-
ment complex, has been used to prevent hemolysis associated 
with PNH. Long-term safety and efficacy data of eculizumab 
for 195 patients with PNH have been reported by Hillmen 
et al. [3]; however, data on Asian patients are scarce because 
of the recent availability of eculizumab to the region. In 
Korea, medical insurance reimbursement of eculizumab be-
gan in 2012 for PNH patients with complications such as 
TE, pulmonary hypertension, or chronic kidney disease 
(CKD). The Korean government reimbursement criteria of 
eculizumab in PNH are complex: all patients receiving eculi-
zumab in Korea not only must have elevated lactate de-
hydrogenase (LDH) levels, but also have at least one compli-
cation before eculizumab treatment. The aim of this study 
was to evaluate clinical outcomes with eculizumab in Korean 
patients with PNH concurrent with AA (PNH/AA) and with-
out AA (classic PNH). 
MATERIALS AND METHODS
Study population and study parameters
Patients ≥18 years of age with PNH diagnosed by flow 
cytometry and treated with eculizumab for more than 6 
months were analyzed in this prospective PNH registry study. 
Patients were categorized into two groups. Patients with 
concurrent AA or a history of AA were classified as PNH/AA; 
those without concurrent disease were categorized as classic 
PNH [4]. Patients with severe AA (i.e., absolute neutrophil 
count (ANC) ＜0.5×109/L, platelets ＜20×109/L, and bone 
marrow cellularity ＜20%) and those who had received eculi-
zumab treatment for less than 6 months were excluded. 
Biochemical indicators of intravascular hemolysis and hema-
tological laboratory values including LDH, hemoglobin, pla-
telet, ANC, reticulocyte count, PNH clones (granulocytes 
and/or erythrocytes), serum creatinine, and estimated glo-
merular filtration rate (eGFR) were assessed at the time of 
eculizumab initiation and at least every 6 months thereafter. 
Transfusion requirement, history and/or presence of clinical 
features including thrombosis, renal failure, pulmonary hy-
pertension, smooth muscle spasm (defined as severe/re-
current abdominal pain requiring opioids), and symptoms 
(chest pain, dyspnea, abdominal pain, dysphagia, erectile 
dysfunction, and hemoglobinuria) were also assessed by the 
treating physician at baseline and every 6 months after ini-
tiation of eculizumab treatment. We collected and analyzed 
the data prospectively. This study was approved by the in-
stitutional review board of all participating hospitals, and 
informed consent was obtained from all participants. 
Eculizumab treatment
All patients were vaccinated against Neisseria meningitidis 
at least 2 weeks prior to starting eculizumab. Eculizumab 
was administered at a weekly dose of 600 mg by intravenous 
infusion from weeks 1 to 4, followed by infusion of 900 
mg at week 5, and then 900 mg biweekly for an indefinite 
period.
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Table 2. Baseline clinical signs and symptoms.
Characteristic (%)
N of patients (%)
PTotal 
(N=46)
Classic 
(N=19)
PNH/AA 
(N=27)
Thromboembolism 19 (41.3) 7 (36.8) 12 (44.4) 0.606a)
Renal failure 20 (43.5) 10 (52.6) 10 (37.0) 0.313a)
Pulmonary hypertension 5 (10.9) 1 (5.3)   4 (14.8) 0.320a)
Smooth muscle spasm 17 (37.0) 5 (26.3) 12 (44.4) 0.210a)
Chest pain 12 (26.1) 7 (36.8)   5 (18.5) 0.163a)
Dyspnea 24 (52.2) 11 (57.9) 13 (48.1) 0.515a)
Abdominal pain 32 (69.6) 14 (73.4) 18 (66.7) 0.611a)
Dysphagia 12 (26.1) 3 (15.8) 9 (33.3) 0.182a)
Erectile dysfunction 6 (24.0)c) 6 (54.5)c) 0 0.001a)
Hemoglobinuria 38 (82.6) 17 (89.5) 21 (77.8) 0.303a)
Transfusion (mean, units) 8.5 (0–37) 7.0 (0–18) 8.0 (0–37) 0.802b)
a)Chi-squared test, b)Mann–Whitney U test, c)male patients only.
Abbreviations: AA, aplastic anemia; PNH, paroxysmal nocturnal 
hemoglobinuria.
Fig. 2. Improvement of anemia after eculizumab. In both patients with 
PNH/AA and classic PNH, hemoglobin levels were significantly 
improved after the first 6 months of eculizumab treatment; the effect 
(hemoglobin above 10 g/dL) was sustained after 36 months. P-values 
compared with baseline were assessed by Wilcoxon signed-rank test. 
Abbreviations: AA, aplastic anemia; ecu, eculizumab; PNH, paroxy-
smal nocturnal hemoglobinuria.
Fig. 1. Reduction in hemolysis after eculizumab. Treatment with 
eculizumab induced rapid and consistent inhibition of hemolysis to 
near normal levels in all patients after 36 months of follow-up. Patients 
with both PNH/AA and classic PNH had significant median change of 
LDH level. P-values compared with baseline were assessed using 
Wilcoxon signed-rank test. 
Abbreviations: AA, aplastic anemia; ecu, eculizumab; PNH, paroxy-
smal nocturnal hemoglobinuria; ULN, upper limit of normal.
Statistical analysis
Data analysis was performed using IBM SPSS version 21.0 
(IBM Corp., Armonk, NY, USA). Differences between the 
two groups (classic PNH vs. PNH/AA) were compared using 
the Student t-test, chi-squared test, or Mann–Whitney U 
test. A Wilcoxon signed-rank test was used to assess changes 
from baseline to specific time points for LDH, hemoglobin, 
and number of units of transfused packed RBCs. A P-value 
of less than 0.05 was considered statistically significant.
RESULTS
Patient characteristics
As of December 2016, a total of 46 patients were enrolled 
who met the inclusion criteria, of which 19 patients (41%) 
were categorized in the classic PNH group and 27 patients 
(59%) in the PNH/AA group. Among the 27 patients in 
the PNH/AA group, 20 had a history of AA and 7 patients 
had AA concurrent with PNH at the time of initiation of 
eculizumab. The median age of the study population was 
46 years (range, 18–73 yr) at eculizumab initiation, and the 
median duration of eculizumab treatment was 34 months 
(range, 6–44 mo). Median LDH fold×upper limit of normal 
(ULN) was 7.3 (range, 2.4–23.7) and GPI-deficient gran-
ulocytes was 92.8% (range, 15.7–100%) at the time of eculizu-
mab treatment.
Table 1 shows the characteristics and baseline laboratory 
findings of each group. Median age, gender ratio, disease 
duration, duration of eculizumab treatment, and laboratory 
parameters such as LDH, hemoglobin, platelets, reticulocytes, 
creatinine, and PNH clone size were similar between the 
two groups, except for ANC count (Table 1). Baseline clinical 
manifestations are described in Table 2. The most common 
finding was hemoglobinuria (82.6%) followed by abdominal 
pain (69.6%), dyspnea (52.2%), renal failure (43.5%), and 
TE (41.3%). The mean number of RBC transfusion units 
was 8.5 (range, 0–37) during the 6 months prior to eculizumab 
treatment and there was no difference between the two 
groups (Table 2).
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Table 3. Anticoagulation use in patients with thromboembolism 
history.
Parameter Total
History of thromboembolism (TE), N (%) 19 (41.3)
Treatment history
Anticoagulation use, N (%) 10 (52.6)
Anticoagulation use during eculizumab treatment, N (%) 6 (31.5)
Ongoing anticoagulation use at current stage, N (%) 3 (50)a)
Stopped anticoagulation use at current stage, N (%) 3 (50)
Duration of anticoagulation during eculizumab 
treatment (mo)
5.9
a)One patient restarted anticoagulation treatment after recurring TE 
event at 36-month follow-up.
Fig. 3. Reduction of transfusion requirement after eculizumab. The 
mean number of packed RBC units transfused was significantly 
reduced from 8.5 units during the 6 months prior to initiation of 
eculizumab to 1.6 units in the first 6 months of treatment, for the total 
study population. P-values compared with baseline were assessed by 
Wilcoxon signed-rank test. 
Abbreviations: AA, aplastic anemia; ecu, eculizumab; PNH, paroxy-
smal nocturnal hemoglobinuria; RBC, red blood cells. 
Effect of eculizumab on hemolysis, anemia, and transfusion 
requirement
Treatment with eculizumab induced rapid inhibition of 
hemolysis. At 6 months post-initiation of eculizumab, LDH 
decreased to near normal levels in all patients, and this effect 
was maintained until the 36-month follow-up (Fig. 1). As 
inhibition of hemolysis was maintained, anemia was also 
improved. At 6 months after initiation of eculizumab, hemo-
globin levels were significantly increased as compared with 
prior to the initiation of eculizumab, and the effect 
(hemoglobin above 10 g/dL) was sustained at 36 months. 
Both PNH/AA and classic PNH patients showed similar im-
provement of anemia (Fig. 2). Next, we analyzed transfusion 
requirement. The mean number of packed RBC units trans-
fused was significantly reduced, from 8.5 units during the 
6 months prior to initiation of eculizumab to 1.6 units in 
the first 6 months of treatment with eculizumab, for the 
total study population; this effect was similar in both the 
PNH/AA and classic PNH groups (Fig. 3). At 36-month fol-
low-up, the mean number of transfused RBC units for the 
PNH/AA group was 0.3 and 0 for the classic PNH group. 
Overall, transfusion independence in the study population 
was achieved by 53.3% within the first 6 months of treatment 
and by 90.9% after 36 months of treatment.
Effect of eculizumab treatment on PNH-related complications
As shown in Table 3, a total 19 patients had a history 
of TE before eculizumab treatment, and 10 of 19 (52.6%) 
used anticoagulation therapy (4 in the classic PNH and 6 
in the PNH/AA group). During the eculizumab treatment 
period, 6 patients (3 in each group) were under anti-
coagulation therapy. Among them, 3 patients discontinued 
anticoagulation following the resolution of TE, and 3 patients 
continued to receive anticoagulation agents with resolution 
of TE. During the study period, only 1 patient with classic 
PNH who stopped anticoagulation after complete resolution 
of TE experienced recurrent TE at the same sites (deep vein 
and pulmonary artery). This patient restarted anticoagulation 
therapy at the 36-month follow-up. 
Nine patients had baseline eGFR less than 60 mL/min/1.73 
m2, of which 5 patients (56%) showed improvement of eGFR 
during eculizumab treatment and 4 patients had stabilized 
eGFR. No patients developed worsening of renal function.
Among patients with a history of pulmonary hypertension 
and smooth muscle spasm, none developed new or recurrent 
symptoms or signs during the eculizumab treatment period. 
Effect of eculizumab on clinical manifestations of PNH
Clinical symptoms and signs were significantly improved 
in the overall study population. Among 32 patients who 
had abdominal pain, 3 patients reported abdominal pain after 
eculizumab treatment (2 in the classic PNH group and 1 
in the PNH/AA group). Among 38 patients with hemoglobi-
nuria and 24 with dyspnea, only 1 patient in each group 
reported symptoms of these conditions after eculizumab 
treatment. Among 6 male patients with erectile dysfunction, 
1 patient with classic PNH reported the condition after eculi-
zumab treatment. None of the patients who had previously 
reported chest pain or dysphagia (12 patients each) com-
plained of such symptoms after eculizumab treatment.
DISCUSSION
To better understand the impact of reducing intravascular 
hemolysis, we analyzed data from the prospective Korean 
PNH registry. We evaluated the hemolysis, anemia parame-
ter, transfusion requirement, PNH-related symptoms and 
complications for PNH patients with or without AA who 
received eculizumab. We hypothesized that all patients treat-
ed with eculizumab would show clinical benefits and that 
eculizumab treatment could thus reduce the risk of pro-
bloodresearch.or.kr Blood Res 2017;52:207-11.
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gressive complications such as TE, pulmonary hypertension, 
and renal failure, regardless of concurrent disorders. As found 
in this analysis, eculizumab treatment showed rapid and 
sustained reduction of hemolysis in all patients with PNH 
through 36 months of follow-up. Decreased hemolysis re-
sulted in the improvement of anemia regardless of a con-
current disorder, and transfusion independence was achieved 
in 90.9% of patients after 36 months of treatment. 
Hemoglobin stabilization and reduced transfusion require-
ments with eculizumab have been described in several studies 
[5-8], and we confirmed that those effects were achieved 
regardless of underlying AA. By reducing intravascular he-
molysis, we also observed that abdominal pain, dysphagia, 
and erectile dysfunction were improved after eculizumab 
treatment.
We previously reported that the prevalence of TE was 
18% in 301 Korean patients with PNH who had not received 
eculizumab, and this was associated with increased risk for 
mortality [9]. In this study, a total of 19 patients reported 
a history of TE at the time of initiation of eculizumab and 
6 had received concomitant anticoagulation therapy. All en-
rolled patients with TE had resolution of TE. However, 1 
patient with classic PNH had recurrence of TE at the same 
sites after discontinuing anticoagulation therapy while on 
eculizumab. This result is similar to that of a previous study 
reporting that 96.4% of patients remained free of TE [3]. 
Renal dysfunction has been well reported in PNH [10] 
and several studies have consistently shown that eculizumab 
has a protective role in renal function [3, 11]. In our study, 
we enrolled 9 patients who had baseline eGFR less than 
60 mL/min/1.73 m2. Among these, 5 patients (56%) showed 
improvement of eGFR during eculizumab treatment and 4 
patients had stabilized eGFR. Because TE and renal impair-
ment are known independent risk factors for mortality in 
Korean PNH patients [12], the effects of eculizumab on these 
risk factors is expected to improve patient survival.
Owing to the relatively recent introduction and approval 
of eculizumab, long-term clinical data are not yet available, 
and data from Asian countries are scarce [10]. The first study 
reporting the efficacy of eculizumab among Asian patients 
with PNH was the AEGIS study from Japan [8]. This trial 
was an open-label, non-comparative, multicenter phase II 
study including 27 patients. Interestingly, the authors com-
pared the effect of eculizumab between PNH patients (N=15) 
and patients with PNH plus AA/myelodysplastic syndrome 
(N=12) and found that there was no difference between 
the two groups in terms of hemolysis, blood transfusion, 
and fatigue score [8]. Our data revealed similar findings, 
providing additional evidence for the role of eculizumab 
in PNH/AA.
In conclusion, clinical outcomes with eculizumab were 
significantly improved compared with the baseline in both 
patients with PNH/AA and those with classic PNH. This 
study demonstrated that eculizumab has a beneficial role 
in the management of patients with PNH/AA, similar to 
that of classic PNH, by inhibiting hemolysis and reducing 
transfusion requirements, thus resulting in the improvement 
of clinical signs and symptoms.
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